Co-Delivery of Paclitaxel and PLK1-Targeted siRNA Using Aptamer-Functionalized Cationic Liposome for Synergistic Anti-Breast Cancer Effects <i>In Vivo</i>

Yu, Song; Bi, Xiongjie; Yang, Lei; Wu, Shanguang; Yu, Yating; Jiang, Bojin; Zhang, Anwen; Lan, Ke; Duan, Siliang

doi:10.1166/jbn.2019.2751

Cited by 76 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another similar formulation was developed by Sheng Yu and colleagues, showing synergistic activity of PDX and Polo-like kinase 1 (PLK-1)-targeting siRNA in limiting the progression of breast cancer. These cationic liposomes were also functionalized with a targeting aptamer (AS1411) to further enhance tumor accumulation [54]. In another report, the use of gemcitabine (Gem) in combination with Myeloid cell leukemia 1 (MCL1)-targeting siRNA in loaded liposomes was shown to be effective in treating pancreatic cancer [55].…”

Section: Liposomesmentioning

confidence: 99%

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

2020

View full text Add to dashboard Cite

RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated gene silencing requires overcoming multiple physiological barriers to achieve efficient delivery of siRNAs into cells in vivo, including into tumor and/or host cells in the tumor micro-environment (TME). Consequently, lipid and polymer-based nanoparticle siRNA delivery systems have been developed to surmount these physiological barriers. In this article, we review the strategies that have been developed to facilitate siRNA survival in the circulatory system, siRNA movement from the blood into tissues and the TME, targeted siRNA delivery to the tumor or specific cell types, cellular uptake, and escape from endosomal degradation. We also discuss the use of various types of lipid and polymer-based carriers for cancer therapy, including a section on anti-tumor nanovaccines enhanced by siRNAs. Finally, we review current and recent clinical trials using NPs loaded with siRNAs for cancer therapy. The siRNA cancer therapeutics field is rapidly evolving, and it is conceivable that precision cancer therapy could, in the relatively near future, benefit from the combined use of cancer therapies, for example immune checkpoint blockade together with gene-targeting siRNAs, personalized for enhancing and fine-tuning a patient’s therapeutic response.

show abstract

Section: Liposomesmentioning

confidence: 99%

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

2020

View full text Add to dashboard Cite

show abstract

“…Lipids or lipid-like materials (lipidoids) are able to form various vesicles, e.g., LNP, liposome, lipid emulsion, lipid implant, with nuclei acids [ 3 , [7] , [8] , [9] , [10] , [11] ]. A series of cationic lipids and ionizable lipids such as 1,2-dioleoyloxy-3-trimethylammonium propane chloride (DOTAP), N-[1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammo- nium chloride (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dilinoleylmethyl-4-dimethylaminobutyrate (Dlin-MC3-DMA) have been investigated for siRNA or mRNA delivery [ 5 , 10 , [12] , [13] , [14] , [15] , [16] , [17] ]. Ionizable LNP (iLNP) is more clinically advanced than other deliver systems in the context of RNA delivery.…”

Section: Introductionmentioning

confidence: 99%

Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle

Yang

Wang

et al. 2020

Bioactive Materials

View full text Add to dashboard Cite

mRNA is a novel class of therapeutic modality that holds great promise in vaccination, protein replacement therapy, cancer immunotherapy, immune cell engineering etc. However, optimization of mRNA molecules and efficient in vivo delivery are quite important but challenging for its broad application. Here we present an ionizable lipid nanoparticle (iLNP) based on iBL0713 lipid for in vitro and in vivo expression of desired proteins using codon-optimized mRNAs. mRNAs encoding luciferase or erythropoietin (EPO) were prepared by in vitro transcription and formulated with proposed iLNP, to form iLP171/mRNA formulations. It was revealed that both luciferase and EPO proteins were successfully expressed by human hepatocellular carcinoma cells and hepatocytes. The maximum amount of protein expression was found at 6 h post-administration. The expression efficiency of EPO with codon-optimized mRNA was significantly higher than that of unoptimized mRNA. Moreover, no toxicity or immunogenicity was observed for these mRNA formulations. Therefore, our study provides a useful and promising platform for mRNA therapeutic development.

show abstract

“…For example, Yu et al [ 30 ] reported that an AS1411-functionalized liposome can simultaneously deliver paclitaxel (PTX), a drug used to treat breast and other of types of cancer, and Polo-like kinase-1 [ 31 ] (PLK-1)-targeted siRNA into MCF-7 breast cancer cells in vitro and in vivo. The simultaneous delivery of PTX and the anti-PLK-1 siRNA synergistically increased the number of apoptotic cells and reduced angiogenesis, relative to liposomal delivery of PTX and the anti-PLK-1 siRNA separately.…”

Section: Targeted Deliverymentioning

confidence: 99%

Recent advances in aptamer applications for analytical biochemistry

Zon

2022

Analytical Biochemistry

View full text Add to dashboard Cite

Aptamers are typically defined as relatively short (20–60 nucleotides) single-stranded DNA or RNA molecules that bind with high affinity and specificity to various types of targets. Aptamers are frequently referred to as “synthetic antibodies” but are easier to obtain, less expensive to produce, and in several ways more versatile than antibodies. The beginnings of aptamers date back to 1990, and since then there has been a continual increase in aptamer publications. The intent of the present account was to focus on recent original research publications, i.e., those appearing in 2019 through April 2020, when this account was written. A Google Scholar search of this recent literature was performed for relevance-ranking of articles. New methods for selection of aptamers were not included. Nine categories of applications were organized and representative examples of each are given. Finally, an outlook is offered focusing on “faster, better, cheaper” application performance factors as key drivers for future innovations in aptamer applications.

show abstract

Co-Delivery of Paclitaxel and PLK1-Targeted siRNA Using Aptamer-Functionalized Cationic Liposome for Synergistic Anti-Breast Cancer Effects In Vivo

Cited by 76 publications

References 0 publications

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle

Recent advances in aptamer applications for analytical biochemistry

Contact Info

Product

Resources

About